 Research analysts at Maxim Group initiated coverage on shares of Capricor Therapeutics NASDAQ:CAPR in a research report issued to clients and investors on Friday, AnalystRatings.com reports. The brokerage set a buy rating and a 12.00 price target on the biotechnology companys stock. Maxim Groups target price points to a potential upside of 83.77 from the ... 